is what filing a shelf registration amounts to at this point in time for Venaxis.
"We have no plans at this time to raise capital". Of course they don't because the company has more than enough cash on hand to clear the FDA and at least begin the process of building out sales/support infrastructure, Yes, certainly additional capital to bolster the balance sheet post approval would be a necessary component of marketing/sales success, but management is well aware that trial data alone will send the PPS significantly higher than the closing price at date of filing.
"Prudent move" because top line results are due out in a mere 6-8 weeks and there is not a single shred of evidence to date indicating that the results aren't going to be outstanding. Hence, management MUST or should anticipate strong upward movement in the stock leading up to and upon release of the data.
In essence, what all this means is that management has simply taken the expected or routine step "TO BE PREPARED" when the value of the shares rise to the higher levels that would warrant consideration to offer shares to raise capital.